The expanded label claim raises a basic question: why would the label be expanded in the first place?
NWBO announced the MAA as DCVax-L for glioblastoma. If label discussions are occurring, I would expect them to relate to the submitted GBM indication, not some broad cancer label.
It seems unlikely MHRA would independently demand a broader label and then make initial approval contingent on working out expanded use beyond the application. Regulators approve what the applicant requests and what the evidence supports.
So if the label is being expanded beyond GBM, that sounds like NWBO would have had to amend the application or seek a variation to pursue a broader indication. That would be a major development. It could affect market size, manufacturing demand, reimbursement, the evidence package, and the approval timeline.
And “prepare accordingly” is doing a lot of work. If an expanded label would require more capacity, more capital spending, more manufacturing readiness, and possibly more delay before revenue, then that sounds material too, especially for a cash strapped company that has been diluting shares to fund operations. A broader label would not just be a regulatory detail. It could change the required investment, commercial plan, manufacturing burden, reimbursement picture, and timing of any revenue.
If that happened, where is the disclosure?
When I question claims like an expanded label, that is not me trying to stop investors from “figuring things out.” It is me asking whether the expanded label theory is actually supported by disclosure, or whether it is just another way to explain away 2.5 years of delay without approval.
Market Data 
Markets 
